New CEO gets off to a good start at Pfizer

30 April 2019

Strong sales performance for breast cancer drug Ibrance (palbociclib) and pneumonia vaccine Prevnar (pneumococcal 7-valent conjugate) helped New York’s Pfizer (NYSE: PFE) on its way to a 9% bump in profits for the first quarter of 2019.

The firm says it took in $13.1 billion sales for the first three months of the year, matching analysts' expectations, with reported earnings per share (EPS) of $0.68.

Reported net income was $3.9 billion, up from $3.6 billion. The company reaffirmed its full year financial guidance, between $52 billion and $54 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK